SPILLO supports R&D teams through unbiased in silico identification of targets and off-targets, revealing mechanisms of therapeutic and adverse drug effects. Using an exclusive, innovative physics-based technology, SPILLO reduces risk, improves outcomes and helps recover value from stalled programs.
Products, services, technology
Proteome-wide identification of targets and off-targets for small molecules, with structural insights on binding sites, including cryptic sites. Elucidation of therapeutic and adverse mechanisms, anticipation of safety liabilities (also rare ADRs), drug rescue, repurposing, and R&D decision-making.
Cooperation possibilities
Project-based collaborations with pharmaceutical and established biotech companies seeking deep mechanistic insight to support internal R&D decisions, safety assessment, and development strategy across drug candidates and marketed or legacy assets.
- https://www.spillo.ch
- +41 76 626 83 00
- Send an email
- Alessandro Di Domizio
Some insights
By uncovering the biomolecular mechanisms behind drug efficacy and adverse effects, SPILLO helps make medicines safer, more effective, and better targeted. Mechanistic insight enables earlier risk reduction, fewer late-stage failures, and more informed, patient-tailored development strategies.
We are proud that SPILLO’s predictions have been experimentally validated in independent studies and published in peer-reviewed journals, demonstrating the ability to address complex real-world drug R&D challenges—particularly in high-risk programs—that remain unresolved with existing approaches.
We look up to organizations that combine scientific rigor with responsibility, transparency, and long-term impact—advancing drug development through deep and reliable mechanistic understanding.
By facilitating qualified connections with pharmaceutical, biotech, and government research organizations facing complex mechanistic, efficacy, or safety challenges in applied drug development, and by ensuring visibility among R&D decision-makers.
Pharmaceutical and biotech R&D, translational science, and drug safety teams, as well as public or government research institutes engaged in applied drug development programs for small-molecule therapeutics.
